NCT06500741Completed
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
Discrete Choice Experiment to Assess the Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Patients With Prostate Cancer
Source: ClinicalTrials.gov · Last updated 6 May 2025
Brief summary (registry, in English)
The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 374 (actual)
- First submitted
- 8 Jul 2024
- Start date
- 22 Nov 2024
- Primary completion date
- 2 Apr 2025
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Diseases
- Prostate cancer
- NCT number
- NCT06500741
What you commit to
- Study type: Observational
- Participants enrolled: 374
- From 22 Nov 2024 to the primary completion date, 2 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Physician exclusion criteria
- None Patient exclusion criteria
- The patient is castration resistant.
- The patient has metastatic PC.
Who the study is looking for
- Physician inclusion criteria
- The physician is a certified urologist or oncologist. The final selection will be adjusted to local practice.
- The physician has cared for at least ten nmHSPC patients in the past year.
- The physician has experience prescribing NHT and ADT. Patient inclusion criteria
- The patient has nmHSPC after radiotheraphy (RT) and/or radical prostatectomy (RP), defined as an adult patient with nmPC who had RT and/or RP.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Analysis Group, Inc. Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.